The method of claim 1 , wherein the patient is a male patient, the sexual dysfunction is erectile dysfunction, the quantity of PDE-5 inhibitor administered and the quantity of PT-141 administered together is sufficient to initiate the desired pharmacological response in the patent and less than the quantity of either PDE-5 inhibitor administered as a monotherapy or PT-141 administered as a monotherapy to treat sexual dysfunction, and the quality of erection score is superior to that obtained from administration of a therapeutically effective amount of a single agent, administered as monotherapy, sufficient to initiate the desired pharmacological response in the patent
Statistical significance was assessed using a two-sided t-test with permutation-based false discovery rate (FDR) correction (1%)
Eligible: Commercial or private insurance Not eligible: Medicare, Medicaid, Tricare, VA, or uninsured Denied coverage
Serving size is 2 Capsules, with 30 servings per container and $3.33 per serving
Administering an iodide supplement between 100 and 300 g/d increased the total antioxidant status in human serum (54)
